These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27545626)

  • 1. [Phosphate binders in renal patients: a point estimate from rationale, through evidences to the real world setting].
    Galassi A; Giovenzana ME; Galbiati E; Auricchio S; Colzani S; Scanziani R
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New Developments in CKD-MBD. New aspects in phosphate binders].
    Yokoyama K
    Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sevelamer versus calcium-based phosphate binders for chronic kidney disease.
    Bravo-Soto GA; Madrid T
    Medwave; 2017 May; 17(Suppl2):e6942. PubMed ID: 28525528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
    Khouzam N; Wesseling-Perry K
    Pediatr Nephrol; 2019 Jan; 34(1):1-10. PubMed ID: 28939921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Hanafusa N
    Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes to calcium-phosphate metabolism associated with chronic nephropathies].
    Blahoš J; Sotorník I
    Vnitr Lek; 2012; 58(7-8):512-8. PubMed ID: 23067156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease.
    Mathew S; Davies M; Lund R; Saab G; Hruska KA
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():43-50. PubMed ID: 16884397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
    Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
    Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease.
    Moe SM
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():51-62. PubMed ID: 16884398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.